Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Gefitinib
57
CHF
CHF 57.00
In stock
SYN-1042-M0011 mgCHF 57.00
SYN-1042-M0055 mgCHF 78.00
SYN-1042-M01010 mgCHF 92.00
SYN-1042-M05050 mgCHF 170.00
SYN-1042-M100100 mgCHF 284.00
Product Details | |
---|---|
Synonyms | ZD1839; Iressa |
Product Type | Chemical |
Properties | |
Formula | C22H24ClFN4O3 |
MW | 446.9 |
CAS | 184475-35-2 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: EGFR - HER2 | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
Gefitinib is a selective, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In NR6wtEGFR and NR6W cells, it inhibits Tyr1173, Tyr992, Tyr1173 and Tyr992 with IC(50) values of 37nM, 37nM, 26nM and 57nM, respectively.
Product References
- ZD1839 ('Iressa') as an anticancer agent: J. Baselga & S.D. Averbuch; Drugs 60, 33 (2000)
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor: F. Ciardiello, et al.; Clin. Cancer Res. 6, 2053 (2000)
- Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor: D. McKillop, et al.; Mol. Cancer Ther. 4, 641 (2005)